AMNEAL PHARMACEUTICALS, INC. Loss Contingency, Receivable
AMNEAL PHARMACEUTICALS, INC. (AMRX) had Loss Contingency, Receivable of $0 as of 2022-12-31, per its 10-K filed 2023-03-03.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyReceivable · last filed 2023-03-03
- 2022-12-31: Loss Contingency, Receivable $0.00.
- 2022-09-30: Loss Contingency, Receivable $73.00M.
- 2022-06-30: Loss Contingency, Receivable $148.50M.
- 2022-03-31: Loss Contingency, Receivable $37.00M.
| Period end | Loss Contingency, Receivable |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-03 |
| 2022-09-30 | $73.00M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $148.50M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $37.00M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $33.00M 10-K · filed 2023-03-03 |
| 2021-09-30 | $33.00M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $33.00M 10-Q · filed 2021-08-09 |
| 2020-12-31 | $6.00M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |